Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …

While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity,
and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely …

PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …

Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor
patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 …

The immune system is the hard-wired host defense mechanism against pathogens as well
as cancer. Five years ago, we pondered the question if the era of cancer immunotherapy …

Most studies focus on the first and second signals of T cell activation. However, the roles of
cytokines in immunotherapy are not fully understood, and cytokines have not been widely …

The innate immune sensing pathways play critical roles in the defense against pathogen
infection, but their roles in cancer immunosurveillance and cancer therapies are less …

Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …

The mechanisms through which immune responses are generated against solid cancers are
well characterized and knowledge of the immune evasion pathways exploited by these …